AGL agilon health, inc. Insider Trading

CLO Zamore Denise bought 5,535 shares of AGL; cluster buy with 2 other insiders in 14 days as stock at -88.8% from 52-week high.

Zamore Denise, Chief Legal Officer, purchased 5,535 shares on 2026-03-09, increasing her holdings from 441,069 to 446,604 shares. This transaction is part of a cluster buy pattern where 2 other insiders also purchased within the past 14 days. The stock is currently trading at $15.94, which is -88.8% from its 52-week high of $142.00, and the company is unprofitable with net income of $-110,207,000.00 over its most recent full fiscal year. The coincident purchasing by multiple executives during a period of significant price decline and ongoing losses provides a data point on insider sentiment, though the lack of disclosed transaction price and the company's fundamental challenges warrant further scrutiny.

CTO Venkatachaliah Girish bought 18,448 shares of AGL; stock down -88.8% from 52-week high despite cluster buy activity.

Venkatachaliah Girish, Chief Technology Officer, purchased 18,448 shares on 2026-03-09, increasing his holdings by 7.1% to 278,607 shares total. The transaction occurs within a 14-day cluster pattern where 2 other insiders also bought, which may indicate coordinated confidence at depressed valuations. However, context tempers this signal: the current price of $15.94 is -88.8% from the 52-week high of $142.00, and the company remains unprofitable with net income of $-110,207,000 for the latest quarter and annual revenue growth of -2.1%. In his prior two purchases at this ticker, the CTO's timing has been mixed—one achieved a 90-day gain of +31.6% while the other declined -45.9% over the same period—offering no clear pattern of prescient buying.

CMO Shaker Benjamin purchases 18,448 shares of AGL; part of 2-insider cluster buy within 14 days as stock trades at $15.94, down 88.8% from 52-week high.

Shaker Benjamin, Chief Markets Officer, acquired 18,448 shares on 2026-03-09, bringing his total holdings to 1,379,774 shares (a 1.4% net increase). This purchase is part of a cluster pattern—2 other insiders also bought within the past 14 days—which may suggest coordinated confidence in the stock's prospects. However, context matters considerably: the stock is trading at $15.94, down 88.8% from its 52-week high of $142.00, and the company remains unprofitable with full-year net income of $-110,207,000.00 and annual revenue growth of -2.1%. Benjamin's same-ticker history shows mixed results: his 2025-03-14 buy delivered +40.2% in 30 days but then declined -45.9% over 90 days, while his 2024-03-14 buy lost -5.4% initially but recovered to +31.6% at the 90-day mark. The insider cluster buy is noteworthy, but the fundamental backdrop—persistent losses and shrinking revenue—combined with the stock's extreme drawdown from its recent peak suggests investors should examine whether this purchasing pattern reflects opportunity recognition or a response to distressed valuation.

Shaker Benjamin (CMO) buys 500,000 AGL shares at $0.60; stock down -90.0% from 52-week high, company unprofitable.

Shaker Benjamin, Chief Markets Officer of Agilon Health, purchased 500,000 shares at $0.60 on 2026-03-02, increasing his holdings to 1,367,674 shares (+57.6%). The timing is notable: at the transaction price of $0.60, the stock trades far below recent levels, and the current price of $14.18 reflects a -90.0% decline from the 52-week high of $142.00. His prior trades at AGL show mixed timing results—a buy on 2025-03-14 experienced a 90d return of -45.9%, while an earlier buy on 2024-03-14 eventually returned +31.6% over 90 days. The company reported $1.4B in latest quarterly revenue but posted negative net income of $-110.2M and remains unprofitable on a full-year basis, with revenue declining -2.1% year-over-year. The purchase occurs in an environment of severe stock-price deterioration and fundamental operational losses, making this a material but mixed-signal event that requires scrutiny of whether this reflects opportunity recognition or reflects other motivations not apparent from price action alone.

Director Wulf John William bought 81,000 shares of AGL at $0.63 on 2025-11-12, increasing holdings by 28.4% to 365.9K shares.

Director Wulf John William purchased 81,000 shares at $0.63 on 2025-11-12, a substantial addition that increased his holdings by 28.4% from 284.9K to 365.9K shares. This buy occurred when the stock traded near its 52-week low ($12.84–$142.00 range, currently $20.80), representing an -85.4% decline from the 52-week high. His prior purchase at this ticker on 2024-12-05 achieved a 90-day return of +3957.8%, demonstrating successful timing on that occasion. The company reported latest-quarter revenue of $1.4B with annual growth of +40.4%, but remains unprofitable with net income of $-110.2M, so the fundamental picture is mixed growth and continued losses.

CTO Girish buys 9,429 AGL shares; cluster activity as 2 other insiders bought in past 14 days

Venkatachaliah Girish, Chief Technology Officer, purchased 9,429 shares on 2025-03-14, increasing his holdings by 6.5% to 155,120 shares. This buy occurs within a broader insider buying cluster—2 other insiders also acquired shares within the past 14 days—signaling coordinated confidence at the executive level. The timing is notable: Girish's prior buy at AGL on 2024-03-14 delivered +31.6% 90-day return, establishing a pattern of well-timed entry points at this ticker. The company's fundamentals present a mixed picture: annual revenue growth of +40.4% demonstrates strong top-line expansion, but a net loss of $-117,615,000.00 over the most recent full fiscal year underscores profitability challenges despite $1,450,932,000.00 in quarterly revenue. The stock has surged +121.5% over 90 days yet remains -42.6% from its 52-week high of $188.00, leaving open questions about whether insiders are accumulating at an attractive entry point or chasing momentum in a loss-making, high-growth business.

CEO Steven buys 42,426 shares of AGL; third open-market purchase, prior two at same ticker posted +2296.3% and +2730.5% 30-day returns.

Steven, CEO & President, purchased 42,426 shares of Agilon Health on 2025-03-14, increasing his holdings to 355,310 shares (+13.6% net change). His prior two open-market purchases at AGL (2024-09-12 and 2023-11-21) each delivered substantial 30-day returns of +2296.3% and +2730.5% respectively, establishing a pattern of exceptionally well-timed accumulation at this ticker. The current stock price of $108.00 represents a -42.6% decline from the 52-week high of $188.00, though the stock has rallied +26.3% over the past 30 days and +121.5% over 90 days. A cluster of 2 other insiders also purchased shares within the past 14 days, indicating coordinated insider accumulation. However, context matters: the company remains unprofitable (net income $-117,615,000.00 for the latest quarter) despite strong topline momentum (annual revenue growth of +40.4%), and the current purchase price is not disclosed in the filing.

CMO Shaker Benjamin purchases 11,786 AGL shares; cluster buy pattern with 2 other insiders in past 14 days

Shaker Benjamin, Chief Markets Officer, acquired 11,786 shares on 2025-03-14, bringing his holdings to 457,058 shares—a 2.6% increase from 445,272 shares held previously. This open-market purchase occurs as part of a cluster pattern, with 2 other insiders also buying within the past 14 days, suggesting coordinated or contemporaneous conviction at current valuations. The stock has rallied 26.3% over the past 30 days and 121.5% over 90 days, climbing from the 52-week low but currently trading at $108.00—42.6% below its 52-week high of $188.00. Benjamin's prior buy at this ticker on 2024-03-14 delivered a 90-day return of +31.6%, demonstrating a pattern of well-timed accumulation at this company. However, context matters: Agilon Health remains unprofitable (net income $-117,615,000 in the latest quarter) despite strong revenue growth of 40.4% annually, and the company carries a substantial $44.5B market cap against negative earnings.

Director McLoughlin Karen bought 25,000 shares of AGL at $2.20; 3 other insiders also bought within 14 days. Stock down 83.5% from 52-week high.

McLoughlin Karen purchased 25,000 shares at $2.20, increasing her holdings by 51.9% to 73,166 shares post-transaction. This buy occurs as part of a cluster pattern in which 3 other insiders also purchased shares within the past 14 days, indicating broad insider participation at depressed price levels. The stock is trading 83.5% below its 52-week high of $339.25, though it has recovered 19.2% over the past 30 days from recent lows. Despite strong annual revenue growth of 59.4% and $1.5B in latest quarterly revenue, the company remains unprofitable with $-117.6M net income over its most recent full fiscal year, presenting a material disconnect between growth and profitability that warrants investor attention.

Director Battaglia Silvana bought 25.1K shares of AGL at $2.01 on 2024-12-11; stock now $56.00 (52-week high $339.25). Cluster buy with 3 other insiders in 14 days.

Battaglia Silvana (Director) purchased 25,062 shares at $2.01, increasing her holdings by 61.0% to 66,144 shares, coinciding with a cluster buy pattern involving 3 other insiders in the past 14 days. The transaction occurred when the stock was trading at a significant discount (-83.5%) to its 52-week high of $339.25, though up 19.2% over the prior 30 days. Agilon Health is currently unprofitable with net income of -$117,615,000 but shows strong revenue growth of 59.4% year-over-year, suggesting confidence in operational trajectory despite near-term earnings pressure. The coordinated buying activity across multiple insiders during a period of depressed valuation relative to historical highs warrants investor attention to the investment thesis underlying the transactions.